Top 10 GLP-1 Medications for Weight Loss and Health in 2026

Semaglutide 2.4mg (Wegovy) is the most comprehensively studied obesity medication in history, with over 17,604 adults in the SELECT trial alone — more than twice the largest tirzepatide study. A selective GLP-1 receptor agonist, it mimics the hormone released after meals to reduce appetite, slow gastric emptying, and modulate reward pathways. FDA approved for chronic weight management in June 2021, Wegovy launched the modern GLP-1 era. The STEP-1 trial showed 14.9% weight loss versus placebo's 2.4% at 68 weeks. The SELECT trial elevated Wegovy to a cardiovascular medicine: a 20% reduction in MACE (HR 0.80), heart failure hospitalization (HR 0.82), and all-cause mortality (HR 0.81) — benefits largely independent of weight loss. Dosing from 0.25mg weekly escalates over 16 weeks to 2.4mg. List price $1,200-$1,349 monthly, offset by NovoCare savings to $199-$349 self-pay. Medicare Bridge begins July 2026. Best for patients with both obesity and established cardiovascular disease.

Semaglutide 7.2mg (Wegovy HD), FDA approved in April 2026, is Novo Nordisk's strategic answer to Tirzepatide (Zepbound)'s efficacy — delivering 20.7% mean weight loss at 72 weeks, nearly matching the 20.9% of tirzepatide and well above standard Wegovy's 14.9% ceiling. By tripling the dose of the same semaglutide molecule proven in the SELECT trial, it retains the cardiovascular protection profile (20% MACE reduction at 2.4mg) while closing the efficacy gap to within 0.2 percentage points. Administered once-weekly via a modified high-dose pen with gradual titration. Notably, introductory pricing through August 2026 is $149 monthly self-pay — matching Orforglipron (Foundayo)'s oral pill price and making it the highest-efficacy injectable at that price. Post-August 2026 pricing may change. GI side effects align with known semaglutide tolerability. Ideal for patients on standard Wegovy who plateaued and want to step up within the same molecule.

Orforglipron (Foundayo) is the most structurally innovative GLP-1 therapy to reach the US market in a decade — a small-molecule non-peptide GLP-1 receptor agonist that is chemically stable and fully absorbed with or without food, unlike semaglutide's oral Rybelsus which requires a narrow fasting window. FDA approved April 1, 2026, it is taken once daily as a standard tablet, eliminating all injection logistics: no refrigeration, sharps disposal, needle anxiety, or injection-site issues. In the ATTAIN trial, the 36mg dose delivered 12.4% weight loss — 33% less than Tirzepatide (Zepbound)'s 20.2% in SURMOUNT-5 — but for an estimated 35% of obesity patients who refuse injectables, this oral efficacy is transformative. Lilly launched it at $149 monthly self-pay, with Medicare Bridge coverage at ~$50 copay from July 1, 2026. Side effects include GLP-1-typical GI symptoms, possibly attenuated by steady oral absorption. Best for needle-averse patients, frequent travelers, or first-time GLP-1 users seeking simplicity.

Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist that represents the leading edge of pharmacological obesity treatment. By simultaneously activating three distinct metabolic receptors — GLP-1 for satiety and insulin secretion, GIP for glucose regulation and fat storage, and glucagon for energy expenditure — retatrutide creates a broader and more powerful metabolic reset than any previously approved agent. Eli Lilly's TRIUMPH-4 Phase 3 trial, results released in December 2025, produced the most dramatic weight loss data ever recorded for a pharmacological intervention: a mean 28.7 percent body weight reduction, approaching outcomes historically associated with bariatric surgery. This number is extraordinary in context — tirzepatide's dual-agonism produced 20.9 percent, meaning the addition of glucagon receptor activation contributed an estimated 8 percentage points of additional weight loss. Lilly has announced NDA filing plans for Q4 2026, meaning US regulatory approval could come in late 2027 if the review proceeds on a standard timeline. The drug is not yet available by prescription anywhere in the world as of May 2026. While efficacy dominates the narrative, real-world tolerability at these efficacy levels must be carefully characterized — greater fat mobilization and more aggressive appetite suppression may amplify GI side effects, and longer-term effects on bone density, lean muscle mass, and rebound weight gain after discontinuation require study. No cardiovascular outcomes trial data is yet available for retatrutide. Despite these limitations, retatrutide belongs in any 2026 GLP-1 ranking because its Phase 3 data are finalized, its regulatory timeline is concrete, and patients and clinicians should understand what is coming within 12 to 18 months. This outperforms #2 on this list, CagriSema, by 6 percentage points in mean weight loss, a 26% relative improvement.

CagriSema is Novo Nordisk's answer to tirzepatide's dual-agonism: a fixed-dose combination of semaglutide (the proven GLP-1 agonist from Wegovy) and cagrilintide, a novel amylin receptor agonist. Amylin is a pancreatic hormone co-secreted with insulin that signals satiety through the brain's area postrema, slowing gastric emptying and reducing meal size through pathways distinct from GLP-1. By combining two complementary satiety mechanisms — GLP-1 and amylin — CagriSema aims to achieve additive appetite suppression without requiring glucagon receptor activation. The REDEFINE-1 Phase 3 trial produced a 22.7 percent mean weight loss, with a remarkable 60 percent of participants achieving 20 percent or greater body weight reduction — a threshold that historically required bariatric surgery. Novo Nordisk filed with the FDA in December 2025, placing potential US approval on a timeline of late 2026 to mid-2027 depending on review speed and any additional data requests. The combination of semaglutide's proven cardiovascular profile from SELECT with the additive amylin mechanism makes CagriSema one of the more compelling pipeline agents: it is not merely incremental but represents a meaningfully different physiological approach. The semaglutide component should inherit some cardiovascular benefit signals from existing SELECT data, though CagriSema-specific CV outcomes will require its own trial. Weekly subcutaneous injection is expected to be the delivery method, consistent with semaglutide's established pen infrastructure. Pricing has not been announced, but Novo Nordisk's existing NovoCare programs suggest competitive patient assistance will be available. CagriSema is positioned to compete directly with tirzepatide at the top of the approved efficacy table once it clears regulatory review. It achieves 22.7% mean weight loss, outperforming tirzepatide's 20.9% by 1.8 percentage points, a 9% relative improvement.

Liraglutide (Saxenda) holds a singular place in the history of obesity pharmacology: it was the first GLP-1 receptor agonist approved specifically for chronic weight management, receiving FDA clearance in December 2014 — nearly seven years before semaglutide's obesity approval and nearly nine years before tirzepatide. A daily subcutaneous injection, liraglutide works through GLP-1 receptor agonism to reduce appetite and slow gastric emptying, the same fundamental mechanism as all later agents in this class. The pivotal SCALE trials established its efficacy: approximately 8 percent body weight reduction versus 2 to 3 percent for placebo at 56 weeks, with 3-year long-term follow-up data providing what remains one of the longest clinical evidence bases in the class. Over a decade of real-world post-market use has produced an extensive safety database — particularly reassuring for the rare but serious concerns (pancreatitis, thyroid effects) that are common questions for all GLP-1 drugs. Liraglutide's 3-year SCALE data also showed durable weight maintenance with continued use, though weight returns after discontinuation similarly to other agents. The primary clinical limitation in 2026 is competitive: the newer once-weekly agents (semaglutide, tirzepatide) produce 14.9 to 20.9 percent weight loss versus liraglutide's approximately 8 percent, and require only one injection per week versus Saxenda's daily dosing. The daily injection burden is a meaningful adherence challenge. However, Saxenda remains relevant for patients who have previously tolerated it well, those whose insurance covers it but not newer agents, and patients who prefer a well-established drug with the longest real-world experience of any GLP-1 obesity medication. Cost has come down modestly with generic competition pending. With over 10 years of real-world data, it is 60% cheaper than the typical rival at $1,300 per month compared to tirzepatide's $1,350, and its efficacy of 8% weight loss is less than half of semaglutide's 14.9%.

Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist primarily approved for type 2 diabetes management, where it has established a strong evidence base through the AWARD trial series. Its weight loss benefit — approximately 3 to 4.7 kg in clinical trials — is modest compared to the newer obesity-approved agents, but its exceptional tolerability profile sets it apart in a meaningful way for a specific patient population. Among all GLP-1 agents, dulaglutide has the lowest reported nausea rate at approximately 10 percent — a full 10 percentage points below semaglutide and 15 points below tirzepatide. For patients who are GLP-1 naive and anxious about the GI side effects that drive early discontinuation, starting with dulaglutide offers the best chance of establishing tolerance before potentially transitioning to a higher-efficacy agent. The AWARD trials demonstrated consistent glycemic control with reductions in HbA1c of 1.4 to 1.5 percentage points, and the REWIND cardiovascular outcomes trial showed significant reduction in MACE (HR 0.88) for patients with established CV disease or multiple risk factors — providing a meaningful cardiovascular evidence base. Dulaglutide is administered via an innovative single-use, fully automated prefilled auto-injector pen that conceals the needle completely, which reduces injection anxiety substantially for new GLP-1 users. Dosing is once weekly at 0.75mg or 1.5mg, with a 3mg and 4.5mg high-dose option approved for additional glycemic and weight benefit. While not FDA approved for obesity as a primary indication, its off-label use for weight management in patients with type 2 diabetes who are GLP-1 intolerant of other agents reflects its clinical niche. Insurance coverage is broad for diabetes indications. Its nausea rate of 10% is 50% lower than semaglutide's 20%, and it costs approximately $800 per month, which is 40% cheaper than the average GLP-1 medication.

Exenatide extended-release (Bydureon BCise) holds the distinction of being the world's first once-weekly GLP-1 receptor agonist approved for clinical use, and it was this dosing convenience innovation — not exenatide twice-daily (Byetta) — that set the template for the entire once-weekly GLP-1 landscape that followed. AstraZeneca developed Bydureon BCise as an easy-to-use, single-dose auto-injector tray that delivers 2mg of exenatide weekly without needle assembly, improving on the original Bydureon powder reconstitution that many patients found cumbersome. As a GLP-1 receptor agonist, exenatide ER reduces HbA1c through glucose-dependent insulin stimulation, suppresses inappropriate glucagon secretion, and reduces appetite — but its weight loss outcomes in clinical trials have consistently been the weakest among once-weekly GLP-1 agents, at approximately 2 to 3 kg versus placebo — a loss 30% lower than semaglutide's average in similar trials. The EXSCEL cardiovascular outcomes trial (n=14,752) demonstrated non-inferiority for cardiovascular safety (HR 0.91, 95% CI 0.83-1.00) but did not demonstrate superiority, unlike semaglutide's SELECT trial. Nausea is reported in 31.7 percent of patients — the highest nausea rate in the class, outperforming liraglutide's 20% rate — and injection-site nodule formation is a distinctive adverse effect specific to the PLGA microsphere formulation. The Bydureon BCise auto-injector requires weekly shaking to resuspend the microspheres and cannot be frozen, adding handling complexity. In 2026, exenatide ER is primarily prescribed for patients with type 2 diabetes who are already stabilized on it, where switching costs (both financial and clinical) outweigh the incremental benefits of newer agents. New prescriptions for exenatide ER for weight management are rare given the dramatically superior alternatives now available — over 90% of new GLP-1 weight loss prescriptions go to semaglutide or tirzepatide. Despite these limitations, it remains in current prescribing for established T2D patients where continuity of care outweighs switching to a newer agent.

Rybelsus (oral semaglutide 3mg, 7mg, 14mg) was a breakthrough achievement in pharmaceutical chemistry when it launched in 2019 — the first oral GLP-1 receptor agonist to successfully overcome the challenge of peptide degradation in the GI tract. Novo Nordisk accomplished this by co-formulating semaglutide with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), an absorption enhancer that temporarily raises gastric pH and facilitates transcellular peptide transport across the stomach lining. However, this mechanism imposes strict dosing constraints that no other GLP-1 medication requires: the tablet must be taken on an empty stomach with no more than 4 ounces (120mL) of water, followed by 30 minutes of continued fasting before any food, drink, or other medications. Missing any of these requirements substantially reduces bioavailability and blunts efficacy. The PIONEER trial series established Rybelsus's clinical profile for type 2 diabetes: meaningful HbA1c reduction and modest weight loss, though the weight reduction at 14mg — approximately 3 to 5 kg — is modest compared to the injectable obesity agents. Importantly, Rybelsus is not FDA approved for obesity or weight management; it is approved only for type 2 diabetes, and its modest weight loss makes it inappropriate as a primary weight management tool in 2026. The commercial context has shifted dramatically with the April 2026 approval of orforglipron (Foundayo), an oral GLP-1 with no dietary restrictions, superior weight loss of 12.4 percent, and equal or lower pricing. For new patients seeking an oral GLP-1, Foundayo is now the preferred choice. Rybelsus retains value primarily for patients with type 2 diabetes who are already stabilized on it or who have specific insurance formulary constraints that favor it.